MOTS-c for Bone Health: What the Evidence Shows
What human and animal studies show about MOTS-c for bone health, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Animal
- Human studies
- 2
- PubMed records, our ledger
- Animal studies
- 2
- PubMed records, our ledger
- Studies we summarised
- 2
- with an outcome for bone health
Evidence for bone health
Each row is an outcome related to bone health from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Bone loss | MOTS-c treatment significantly alleviated bone loss on micro-CT in ovariectomized mice. | Animal · mouse (not a human result) | Biochemical and biophysical research communications 2016, PMID 27237975 |
| Type I collagen synthesis | MOTS-c increased type I collagen synthesis in cultured human osteoblasts. | In vitro (not a human result) | European review for medical and pharmacological sciences 2019, PMID 31081069 |
PubMed records for MOTS-c and bone health: 2 human, 2 animal (search counts, not studies we reviewed). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Bone loss in plain terms
MedlinePlus defines osteoporosis as a disease in which bones become weak and likely to fracture.[3]
What MOTS-c studies measured closest to bone health
In mice whose ovaries were removed, MOTS-c at 5 mg/kg once a day for 12 weeks significantly alleviated bone loss on micro-CT; this is a per-kilogram mouse dose and an animal result.[1]
The mouse paper reports that MOTS-c inhibited osteoclast differentiation and raised phosphorylated AMPK levels.[1]
In a human bone-cell line (hFOB1.19) in a dish, 0.5 micromolar MOTS-c for 48 hours raised cell viability, and MOTS-c increased type I collagen genes through the TGF-beta/SMAD pathway.[2]
The goal ledger's dated PubMed count for MOTS-c with osteoporosis terms was 2 records tagged human and 2 tagged animal-only.
Calculated from source our PubMed count ledger; goal osteoporosis; peptide MOTS-c; date 2026-10-02; query ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (osteopor*[tiab] OR osteopeni*[tiab] OR "bone mineral density"[tiab] OR "bone density"[tiab] OR "bone loss"[tiab] OR "bone mass"[tiab] OR "fragility fracture"[tiab] OR "fragility fractures"[tiab] OR "bone health"[tiab]); human filter AND humans[mh]; animal filter AND (animals[mh] NOT humans[mh]); human count 2; animal count 2. Formula: counts as recorded in the goals.json ledger; tagged records are not necessarily treatment studies
Other peptides people research for bone health
Common questions
Does MOTS-c help with bone health?
The strongest study we summarise for bone health is animal evidence, across 2 studies with an outcome for bone health. That is not proof it works in people.
Is MOTS-c approved for bone health?
No. MOTS-c is not FDA approved for any use, including bone health.
Does MOTS-c help bone density?
It reduced ovariectomy-induced bone loss in mice; no study in people with osteoporosis is cited here.[1]
Is the 5 mg/kg mouse dose a human dose?
No: it is a per-kilogram dose given to mice, and this page does not convert it to people.[1]
More on MOTS-c
Sources
- 1Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation.Biochemical and biophysical research communications · 2016PMID 27237975Accessed 2 Oct 2026
- 2MOTS-c improves osteoporosis by promoting the synthesis of type I collagen in osteoblasts via TGF-β/SMAD signaling pathway.European review for medical and pharmacological sciences · 2019PMID 31081069Accessed 2 Oct 2026
- 3Official web pageOfficial web page · web page
Found an error? Report a correction.